Live Breaking News & Updates on Initial Clinical Data

Stay updated with breaking news from Initial clinical data. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Freeline Therapeutics Holdings (FRLN) Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201

Freeline Therapeutics Holdings (FRLN) Reports Positive Initial Clinical Data from First Cohort of Phase 1/2 GALILEO-1 Trial of FLT201
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Baja California , Michael Parini , Pamela Foulds , Pilar Giraldo , Spanish Foundation For The Study , Freeline Therapeutics Holdings , Spanish Foundation , Gaucher Disease , Chief Medical , Chief Executive , Initial Clinical Data ,

Investegate |Syncona Limited Announcements | Syncona Limited: Freeline presents data in haemophilia B

Investegate |Syncona Limited Announcements | Syncona Limited: Freeline presents data in haemophilia B
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.

United States , New Zealand , United Kingdom , City Of , Michael Parini , Arne Naeveke , Collins Fergus Witt , Pamela Foulds , Company Phase , International Society On Thrombosis , Data Monitoring Committee , World Federation Of Hemophilia , Exchange Commission , Company Annual Report On Form , Haemostasis Congress , Syncona Ltd , United Kingdom Or European Union , Head Of Corporate Communications , Freeline Therapeutics Holdings , International Society , Chief Investment Officer , Syncona Investment Management Limitedand Chair , Confirmation Study , Guy Young , Syncona Limited , Julia Bradshaw ,

Purple Biotech : NT219 was Well-tolerated with Minimal Adverse Events in Initial Clinical Data from Ongoing Phase 1/2 Clinical Trial in Adults with Advanced Solid Tumors (Form 6-K)

Message :
Required fields
NT219 was Well-tolerated with Minimal Adverse Events in Initial Clinical Data from Ongoing Phase 1/2 Clinical Trial in Adults with Advanced Solid Tumors
Partial Response Observed in a Patient with Refractory Gastroesophageal Junction Cancer
REHOVOT, Israel, June 4, 2021 - Purple Biotech Ltd. ( Purple Biotech , or the Company ) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class, effective and durable therapies by overcoming tumor immune evasion and drug resistance, announced today the presentation of new data from the first dose level cohort of its ongoing Phase 1/2 clinical trial of NT219, at the 2021 ASCO Annual Meeting, being held virtually June 4-8, 2021. The Phase 1/2 study is evaluating NT219 as monotherapy for the treatment of solid tumors, in addition to a subsequent dose escalation of NT219 in combination with cetuximab, an epithelial growth factor receptor (EGFR) blocking monoclonal antibody, for the tr ....

United States , South Korea , Gil Efron , Bertrandc Liang , Megan Humphreys , Alberto Bessudo , Chuck Padala , Exchange Commission , Company Contact , Purple Biotech Ltd , California Cancer Associates For Research Excellence , Drug Administration , Bristol Myers Squibb , Coeptis Pharmaceuticals , Minimal Adverse Events , Initial Clinical Data , Ongoing Phase , Advanced Solid , Response Observed , Refractory Gastroesophageal Junction , Purple Biotech , California Cancer Associates , Chief Medical Officer , Burke Therapeutics , Looking Statements , Safe Harbor ,